Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Faeth Therapeutics Reports 33% ORR in Phase 2 PIKTOR Trial for Endometrial Cancer

Faeth Therapeutics released positive topline Phase 2 data for its PIKTOR combination therapy in patients with advanced endometrial cancer. The study demonstrated a 33% objective response rate and manageable safety profile, clearing the way for a Phase 3 registrational trial.

Doctor, medical, medicine, health. Stock photo illustrating Faeth Therapeutics' other story.
Faeth Therapeutics, Inc. · Healthcare · Photo: DarkoStojanovic / Pixabay

Key highlights

  • Confirmed objective response rate of 33% observed in efficacy-evaluable patients
  • Preliminary median progression-free survival reached 7.4 months with a 6-month PFS rate of 62%
  • Confirmed ORR increased to 44% specifically among patients with PIK3CA mutations
  • Overall disease control rate stood at 83% across the evaluable patient population
  • Low discontinuation rate of 5% due to treatment-related adverse events during the trial

Phase 2 Clinical Outcomes

The PIK-201 trial evaluated PIKTOR, an all-oral combination of serabelisib and sapanisertib, administered alongside paclitaxel for patients with advanced endometrioid endometrial cancer and PAM pathway mutations. As of October 30, 2026, confirmed objective responses were identified in 12 of 36 evaluable patients. The safety profile indicated that treatment-related hyperglycemia occurred in 12% of patients and stomatitis in 21%, with both side effects being predominantly low-grade. These results were achieved in a heavily pre-treated population where patients had a median of two prior lines of therapy, ranging from one to four lines.

Strategic Development Path

  • Advancement of PIKTOR into a Phase 3 registrational trial pending regulatory alignment
  • Targeting of the high-prevalence PI3K pathway alterations in endometrial cancer
  • Utilization of multi-node inhibition to extend progression-free survival beyond standard chemotherapy
  • Expansion of clinical evidence following the FDA Fast Track designation granted in August 2026
  • Continuation of the Phase 1b/2 PIK-101 trial in advanced breast cancer with data expected in 2027

Management Perspective on Efficacy

“We believe these data support the multi-nodal PAM targeting hypothesis, whereby more complete inhibition of the pathway may drive durable responses and extend progression-free survival without the safety limitations of single-node inhibitors.”

Anand Parikh, Co-Founder and CEO, Faeth Therapeutics

Corporate and Financial Standing

Faeth Therapeutics maintains a robust liquidity position with $174.8 million in cash and marketable securities as reported in early November 2026. This capital is projected to support ongoing operations and clinical development for at least 12 months. The company, which rebranded to its current name and ticker symbol FTH in June 2026, currently reports no revenue or order backlog as it focuses on its clinical-stage pipeline. Market response to the Phase 2 data saw the share price increase by 10.69%, reflecting investor interest in the upcoming Phase 3 transition.

Faeth Therapeutics, Inc. share price · last month
Line chart of Faeth Therapeutics, Inc.'s share price over the last month, from $19.44 on 19 Oct → $9.28 on 16 Nov; our story on 9 Nov at $22.05.

Down 57.9% since our story on 9 Nov: $22.05 when we broke it → $9.28 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$19.44
20 Oct$20.79
21 Oct$20.57
22 Oct$20.10
23 Oct$17.08
26 Oct$16.83
27 Oct$19.11
28 Oct$19.20
29 Oct$18.75
30 Oct$18.69
2 Nov$19.23
3 Nov$19.65
4 Nov$19.99
5 Nov$19.92
6 Nov$22.05
9 Nov$12.68
10 Nov$12.92
11 Nov$13.35
12 Nov$10.65
13 Nov$10.03
16 Nov$9.28
Earlier announcements by Faeth Therapeutics, Inc.
DateAnnouncementAmount
03 Nov 2026Third quarter 2026 financial results and operational updatesSource: morningstar.com–
17 Aug 2026FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancerSource: businesswire.com–
04 Aug 2026Second quarter 2026 financial results and operational updatesSource: businesswire.com–
15 Jun 2026Corporate name changed to Faeth Therapeutics, Inc. and ticker symbol changed to FTHSource: investors.faeththerapeutics.com–
15 May 2026First quarter 2026 financial results and corporate updateSource: investors.faeththerapeutics.com–
18 Feb 2026Acquisition of Faeth Therapeutics and concurrent private placementSource: businesswire.com$200.0 Million

Management commentary

“In PIK-201, PIKTOR delivered a preliminary estimated median PFS of 7.4 months, which we believe compares favorably to the 3-4 months typical for salvage chemotherapy alone, or the 6-7 months observed with newer treatments including TOPO1-based ADCs.”

Anand Parikh, Co-Founder and Chief Executive Officer
Faeth Therapeutics, Inc. · financial snapshot
Share price$22.05
Market cap$570M
1-month price change-11.52%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

Current report filing by Faeth Therapeutics announcing positive topline Phase 2 results for the PIK-201 trial.

Read the filing ↗

Track Faeth Therapeutics, Inc. live

Get the next Faeth Therapeutics, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.